Expulsion and continuation rates of the levonorgestrel 52 mg intrauterine system was similar among nulligravid and parous users.
LNG-IUS
clinical performance
expulsion
intrauterine device
nulligravidas
parous users
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
28
09
2021
received:
03
07
2021
accepted:
27
10
2021
pubmed:
30
10
2021
medline:
14
7
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
To compare the expulsion and continuation rates of the levonorgestrel (LNG) 52 mg intrauterine system (IUS) in a cohort of nulligravid and parous users. We conducted a retrospective cohort study that included 996 participants in whom we placed an LNG-IUS, and the participants were monitored for up to 5 years after device placement. We identify 498 nulligravid participants in the medical record database between 2012 and 2020. Each nulligravida was paired with a parous users who had an LNG-IUS inserted on the same day, just before or after the nulligravida. The Kaplan-Meier method and the log-rank test were used to compare the survival curves of the two groups. By the fifth year of use, the expulsion rates were 7.6/100 and 8.2/100 women-years (W-Ys) and the continuation rates were 641/100 W-Ys and 65.4/100 W-Ys without difference among nulligravid and parous users, respectively (P = 0.782 and P = 0.564, respectively). We observed 29 and 31 expulsions among nulligravid and parous users, respectively. Nulligravid and parous participants who used the 52 mg LNG-IUS showed similar expulsion and continuation rates during five years of use.
Substances chimiques
Contraceptive Agents, Female
0
Levonorgestrel
5W7SIA7YZW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318-324Subventions
Organisme : Fundação de Apoio à Pesquisa do Estado de São Paulo (FAPESP)
ID : 2015/20504-9
Organisme : Brazilian National Research Council (CNPq)
ID : 573747/2008-3
Informations de copyright
© 2021 International Federation of Gynecology and Obstetrics.
Références
Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.
Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15-44: United States, 2011-2013. Natl Health Stat Report. 2015;86:1-14.
Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol. 2014;123(3):585-592.
Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105-1113.
Bahamondes MV, Bahamondes L. Intrauterine device use is safe among nulligravidas and adolescent girls. Acta Obstet Gynecol Scand. 2021;100(4):641-648.
Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hillis SD, Marchbanks PA. Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol. 2012;119(4):762-771.
Wang Z, Lou C, Jin L, et al. Attitudes and practices related to intrauterine devices for nulliparous women among Chinese health care providers. Reprod Health. 2019;16(1):10.
Canteiro R, Bahamondes MV, dos Santos FA, Espejo-Arce X, Marchi NM, Bahamondes L. Length of the endometrial cavity as measured by uterine sounding and ultrasonography in women of different parities. Contraception. 2010;81(6):515-519.
Bahamondes MV, Monteiro I, Canteiro R, AoS F, Bahamondes L. Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynecol Obstet. 2011;113(1):50-53.
Zgliczynska M, Kocaj K, Szymusik I, Dutsch-Wicherek MM, Ciebiera M, Kosinska-Kaczynska K. Levonorgestrel-releasing intrauterine system as a contraceptive method in nulliparous women: a systematic review. J Clin Med. 2020;9(7):2101.
Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception. 2011;84(5):e11-e16.
Madden T, McNicholas C, Zhao Q, Secura GM, Eisenberg DL, Peipert JF. Association of age and parity with intrauterine device expulsion. Obstet Gynecol. 2014;124(4):718-726.
Foran T, Butcher BE, Kovacs G, Bateson D, O'Connor V. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review. Eur J Contracept Reprod Health Care. 2018;23(5):379-386.
Vaitsiakhovich T, Filonenko A, Lynen R, Endrikat J, Gerlinger C. Cross design analysis of randomized and observational data-Application to continuation rates for a contraceptive intra uterine device containing Levonorgestrel in adolescents and adults. BMC Women Health. 2018;18(1):180.
Gemzell-Danielsson K, Apter D, Hauck B, et al. The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial. PLoS One. 2015;10(9):e0135309.
Curtis KM, Tepper NK, Jatlaoui TC, et al. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
Díaz J, Pinto Neto AM, Bahamondes L, Díaz M, Arce XE, Castro S. Performance of the copper T 200 in parous adolescents: are copper IUDs suitable for these women? Contraception. 1993;48(1):23-28.
Simonatto P, Bahamondes MV, Fernandes A, Silveira C, Bahamondes L. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system. J Obstet Gynaecol Res. 2016;42(5):554-559.
Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007;75(6 Suppl):S8-S11.
Eisenberg DL, Schreiber CA, Turok DK, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015;92(1):10-16.
Teal SB, Turok DK, Chen BA, Kimble T, Olariu AI, Creinin MD. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. Obstet Gynecol. 2019;133(1):63-70.
Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69(5):407-412.
Harvey C, Bateson D, Wattimena J, Black KI. Ease of intrauterine contraceptive device insertion in family planning settings. Aust N Z J Obstet Gynaecol. 2012;52(6):534-539.